Alembic Pharmaceuticals receives USFDA tentative approval for Bosutinib tablets
Alembic Pharmaceuticals announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Latest Updates
We train professionals to see quality not as a checklist but as a mindset
How does IGMPI’s training ecosystem directly address the root causes of patient safety lapses such as weak documentation,…
Syngene International announces winners of its annual science quiz ‘Synquizitive’
Syngene International, an integrated research, development and manufacturing services organisation, today announced the winners of…
Ahead of union budget, pharma industry seeks R&D boost, GST rationalisation
Anil Matai, Director General, OPPI:
"As India approaches the upcoming Union Budget, OPPI believes that there is an opportunity…
Odisha’s pharma pitch
The recently held Odisha Pharma Summit 2025, the state’s first dedicated summit focused on pharmaceuticals, medical devices, and…
Quality Trailblazer emphasises that leadership commitment is non-negotiable
What motivated you to write Quality Trailblazer, and how does it address the most pressing quality challenges faced by the Indian…
Granules Pharmaceuticals receives FDA tentative approval for gDYANAVEL XR
Granules Pharmaceuticals, a wholly owned subsidiary of Granules India, has received tentative approval (TA) from the US Food and…
Nimesulide and patient safety: Lessons from global drug regulation
Recently, the Indian Ministry of Health and Family Welfare issued a government resolution banning the use of Nimesulide above 100…
Supriya Lifescience ramps up capacity and global readiness for next phase of growth
Supriya Lifescience has built a strong global presence in Active Pharmaceutical Ingredients. What has guided this journey?
Our…
Sharp Sterile Manufacturing increases capacity with $28 million investment
Sharp Sterile Manufacturing has announced a $28 million expansion of its site in Lee, Massachusetts. The enhanced state-of-the-art…
Sigachi Industries appoints Atul Dhavle as Chief People Officer
Sigachi Industries, a leading global manufacturer of pharmaceutical excipients and active pharmaceutical ingredients (APIs),…
Separate license regime for bulk drugs, API and KSMs, under govt’s consideration
The government is considering a separate licensing framework for bulk drugs, active pharmaceutical ingredients (APIs) and key…
Dr. Reddy’s launches Hevaxin, a novel recombinant Hepatitis E vaccine in India
Dr. Reddy’s Laboratories announced the launch of Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus…
Leadership imperative shaping India’s healthcare and pharma landscape in 2026
India’s healthcare and pharmaceutical industries stand at an inflection point. The sector grew at a remarkable 17.5 per cent CAGR…
Advanced excipients could emerge as India’s next big pharma advantage
When the Central Drugs Standard Control Organization (CDSCO) revised Good Manufacturing Practice norms under Schedule M in…
Pandorum Technologies, Nucelion Therapeutics partner to manufacture exosome-based therapy for ocular…
Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue…
Under amended guidelines, pharma firms may no longer have to appear in courts for ‘minor…
Pharmaceutical firms may no longer have to appear in courts in case of "certain minor contraventions" and instead, they can pay a…
Results win customers. Leadership discipline keeps them
What inspired you to write The Dual Mandate in B2B, and how is it different from your earlier book?
My inspiration came from a…
PHARMEXCIL engages in high-level meetings to discuss roadmap for India’s generic pharma exports
The leadership of Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) held a series of high-level meetings with senior…
2025 in review: How India pharma rewired its deal playbook
India’s pharmaceutical sector has continued to attract sustained investor interest, even amid periods of broader market…